Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study

Abstract Background Hemodialysis patients are among high-risk groups for COVID-19. Africa is the continent with the lowest number of cases in the general population but we have little information about the disease burden in dialysis patients. Objectives This study aimed to describe the seroprevalenc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sidy Mohamed Seck, Moustapha Mbow, Yaya Kane, Mouhamadou Moustapha Cisse, Gnagna Faye, Adama Kama, Moussa Sarr, Pamela Nitcheu, Mohamed Dahaba, Ibrahima Mbemba Diallo, Mame Selly Diawara, Lotingo Nehemie Motoula Latou, Yacine Dia, Souleymane Mboup
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	SARS-CoV-2 COVID-19 Seroprevalence Hemodialysis Senegal Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/9f8c8dadb70148b4a893b7be4b1e684b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9f8c8dadb70148b4a893b7be4b1e684b
record_format	dspace
spelling	oai:doaj.org-article:9f8c8dadb70148b4a893b7be4b1e684b2021-11-21T12:42:29ZPrevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study10.1186/s12882-021-02582-w1471-2369https://doaj.org/article/9f8c8dadb70148b4a893b7be4b1e684b2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12882-021-02582-whttps://doaj.org/toc/1471-2369Abstract Background Hemodialysis patients are among high-risk groups for COVID-19. Africa is the continent with the lowest number of cases in the general population but we have little information about the disease burden in dialysis patients. Objectives This study aimed to describe the seroprevalence of SARS-CoV-2 antibodies in the hemodialysis population of Senegal. Patients and methods We conducted a multicenter cross-sectional survey, between June and September 2020 involving 10 public dialysis units randomly selected in eight regions of Senegal. After seeking their consent, we included 303 patients aged ≥ 18 years and hemodialysis for ≥ 3 months. Clinical symptoms and biological parameters were collected from medical records. Patients’ blood samples were tested with Abbott SARS-CoV-2 Ig G assay using an Architect system. Statistical tests were performed with STATA 12.0. Results Seroprevalence of SARS-CoV-2 antibodies was 21.1% (95% CI = 16.7–26.1%). We noticed a wide variability in SARS-CoV-2 seroprevalence between regions ranging from 5.6 to 51.7%. Among the 38 patients who underwent nasal swab testing, only six had a PCR-confirmed infection and all of them did seroconvert. Suggestive clinical symptoms were reported by 28.1% of seropositive patients and the majority of them presented asymptomatic disease. After multivariate analysis, a previous contact with a confirmed case and living in a high population density region were associated with the presence of SARS-CoV-2 antibodies. Conclusion This study presents to our knowledge the first seroprevalence data in African hemodialysis patients. Compared to data from other continents, we found a higher proportion of patients with SARS-CoV-2 antibodies but a lower lethality rate.Sidy Mohamed SeckMoustapha MbowYaya KaneMouhamadou Moustapha CisseGnagna FayeAdama KamaMoussa SarrPamela NitcheuMohamed DahabaIbrahima Mbemba DialloMame Selly DiawaraLotingo Nehemie Motoula LatouYacine DiaSouleymane MboupBMCarticleSARS-CoV-2COVID-19SeroprevalenceHemodialysisSenegalDiseases of the genitourinary system. UrologyRC870-923ENBMC Nephrology, Vol 22, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 COVID-19 Seroprevalence Hemodialysis Senegal Diseases of the genitourinary system. Urology RC870-923
spellingShingle	SARS-CoV-2 COVID-19 Seroprevalence Hemodialysis Senegal Diseases of the genitourinary system. Urology RC870-923 Sidy Mohamed Seck Moustapha Mbow Yaya Kane Mouhamadou Moustapha Cisse Gnagna Faye Adama Kama Moussa Sarr Pamela Nitcheu Mohamed Dahaba Ibrahima Mbemba Diallo Mame Selly Diawara Lotingo Nehemie Motoula Latou Yacine Dia Souleymane Mboup Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study
description	Abstract Background Hemodialysis patients are among high-risk groups for COVID-19. Africa is the continent with the lowest number of cases in the general population but we have little information about the disease burden in dialysis patients. Objectives This study aimed to describe the seroprevalence of SARS-CoV-2 antibodies in the hemodialysis population of Senegal. Patients and methods We conducted a multicenter cross-sectional survey, between June and September 2020 involving 10 public dialysis units randomly selected in eight regions of Senegal. After seeking their consent, we included 303 patients aged ≥ 18 years and hemodialysis for ≥ 3 months. Clinical symptoms and biological parameters were collected from medical records. Patients’ blood samples were tested with Abbott SARS-CoV-2 Ig G assay using an Architect system. Statistical tests were performed with STATA 12.0. Results Seroprevalence of SARS-CoV-2 antibodies was 21.1% (95% CI = 16.7–26.1%). We noticed a wide variability in SARS-CoV-2 seroprevalence between regions ranging from 5.6 to 51.7%. Among the 38 patients who underwent nasal swab testing, only six had a PCR-confirmed infection and all of them did seroconvert. Suggestive clinical symptoms were reported by 28.1% of seropositive patients and the majority of them presented asymptomatic disease. After multivariate analysis, a previous contact with a confirmed case and living in a high population density region were associated with the presence of SARS-CoV-2 antibodies. Conclusion This study presents to our knowledge the first seroprevalence data in African hemodialysis patients. Compared to data from other continents, we found a higher proportion of patients with SARS-CoV-2 antibodies but a lower lethality rate.
format	article
author	Sidy Mohamed Seck Moustapha Mbow Yaya Kane Mouhamadou Moustapha Cisse Gnagna Faye Adama Kama Moussa Sarr Pamela Nitcheu Mohamed Dahaba Ibrahima Mbemba Diallo Mame Selly Diawara Lotingo Nehemie Motoula Latou Yacine Dia Souleymane Mboup
author_facet	Sidy Mohamed Seck Moustapha Mbow Yaya Kane Mouhamadou Moustapha Cisse Gnagna Faye Adama Kama Moussa Sarr Pamela Nitcheu Mohamed Dahaba Ibrahima Mbemba Diallo Mame Selly Diawara Lotingo Nehemie Motoula Latou Yacine Dia Souleymane Mboup
author_sort	Sidy Mohamed Seck
title	Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study
title_short	Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study
title_full	Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study
title_fullStr	Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study
title_full_unstemmed	Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study
title_sort	prevalence of sars-cov-2 antibodies in hemodialysis patients in senegal: a multicenter cross-sectional study
publisher	BMC
publishDate	2021
url	https://doaj.org/article/9f8c8dadb70148b4a893b7be4b1e684b
work_keys_str_mv	AT sidymohamedseck prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT moustaphambow prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT yayakane prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT mouhamadoumoustaphacisse prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT gnagnafaye prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT adamakama prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT moussasarr prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT pamelanitcheu prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT mohameddahaba prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT ibrahimambembadiallo prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT mamesellydiawara prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT lotingonehemiemotoulalatou prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT yacinedia prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy AT souleymanemboup prevalenceofsarscov2antibodiesinhemodialysispatientsinsenegalamulticentercrosssectionalstudy
_version_	1718418841746276352

Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study

Ejemplares similares